201 related articles for article (PubMed ID: 34455585)
1. Targeting the non-ATP-binding pocket of the MAP kinase p38γ mediates a novel mechanism of cytotoxicity in cutaneous T-cell lymphoma (CTCL).
Zhang XH; Chen CH; Li H; Hsiang J; Wu X; Hu W; Horne D; Nam S; Shively J; Rosen ST
FEBS Lett; 2021 Oct; 595(20):2570-2592. PubMed ID: 34455585
[TBL] [Abstract][Full Text] [Related]
2. Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma.
Zhang XH; Nam S; Wu J; Chen CH; Liu X; Li H; McKeithan T; Gong Q; Chan WC; Yin HH; Yuan YC; Pillai R; Querfeld C; Horne D; Chen Y; Rosen ST
J Invest Dermatol; 2018 Nov; 138(11):2377-2387. PubMed ID: 29758280
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
4. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
Wozniak MB; Villuendas R; Bischoff JR; Aparicio CB; Martínez Leal JF; de La Cueva P; Rodriguez ME; Herreros B; Martin-Perez D; Longo MI; Herrera M; Piris MA; Ortiz-Romero PL
Haematologica; 2010 Apr; 95(4):613-21. PubMed ID: 20133897
[TBL] [Abstract][Full Text] [Related]
5. Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis.
Abdulrahman N; Leo R; Boumenar HA; Ahmad F; Mateo JM; Jochebeth A; Al-Sowaidi NK; Sher G; Ansari AW; Alam M; Uddin S; Ahmad A; Steinhoff M; Buddenkotte J
Leuk Lymphoma; 2023 Dec; 64(14):2236-2248. PubMed ID: 37708450
[TBL] [Abstract][Full Text] [Related]
6. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
[TBL] [Abstract][Full Text] [Related]
7. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
[TBL] [Abstract][Full Text] [Related]
8. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the Effect of Gentian Violet on Apoptosis and Proliferation in Cutaneous T-Cell Lymphoma in an In Vitro Study.
Wu J; Wood GS
JAMA Dermatol; 2018 Oct; 154(10):1191-1198. PubMed ID: 30167641
[TBL] [Abstract][Full Text] [Related]
10. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP.
Sumarni U; Reidel U; Eberle J
Cells; 2021 Apr; 10(5):. PubMed ID: 33922439
[TBL] [Abstract][Full Text] [Related]
11. NLRP3 Regulates IL-4 Expression in TOX
Huanosta-Murillo E; Alcántara-Hernández M; Hernández-Rico B; Victoria-Acosta G; Miranda-Cruz P; Domínguez-Gómez MA; Jurado-Santacruz F; Patiño-López G; Pérez-Koldenkova V; Palma-Guzmán A; Licona-Limón P; Fuentes-Pananá EM; Lemini-López A; Bonifaz LC
Front Immunol; 2021; 12():668369. PubMed ID: 34220814
[TBL] [Abstract][Full Text] [Related]
12. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
Clin Cancer Res; 2002 May; 8(5):1234-40. PubMed ID: 12006543
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.
Kohnken R; McNeil B; Wen J; McConnell K; Grinshpun L; Keiter A; Chen L; William B; Porcu P; Mishra A
J Invest Dermatol; 2019 Sep; 139(9):1966-1974.e3. PubMed ID: 30876800
[TBL] [Abstract][Full Text] [Related]
14. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
[TBL] [Abstract][Full Text] [Related]
15. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.
Chakraborty AR; Robey RW; Luchenko VL; Zhan Z; Piekarz RL; Gillet JP; Kossenkov AV; Wilkerson J; Showe LC; Gottesman MM; Collie NL; Bates SE
Blood; 2013 May; 121(20):4115-25. PubMed ID: 23532732
[TBL] [Abstract][Full Text] [Related]
16. Epigenetically Enhanced PDT Induces Significantly Higher Levels of Multiple Extrinsic Pathway Apoptotic Factors than Standard PDT, Resulting in Greater Extrinsic and Overall Apoptosis of Cutaneous T-cell Lymphoma.
Salva KA; Kim YH; Rahbar Z; Wood GS
Photochem Photobiol; 2018 Sep; 94(5):1058-1065. PubMed ID: 29675945
[TBL] [Abstract][Full Text] [Related]
17. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
18. p38gamma mitogen-activated protein kinase integrates signaling crosstalk between Ras and estrogen receptor to increase breast cancer invasion.
Qi X; Tang J; Loesch M; Pohl N; Alkan S; Chen G
Cancer Res; 2006 Aug; 66(15):7540-7. PubMed ID: 16885352
[TBL] [Abstract][Full Text] [Related]
19. TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL-2R signalling pathway.
Zhu M; Yang L; Shi X; Gong Z; Yu R; Zhang D; Zhang Y; Ma W
J Cell Mol Med; 2020 Jan; 24(1):984-995. PubMed ID: 31742861
[TBL] [Abstract][Full Text] [Related]
20. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
